Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles
Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles
复制标题
DOI：
10.1515/dmpt-2018-0032
复制
发表时间：
2019-03-01
影响因子：
--
通讯作者：
Hamidi, Mehrdad
中科院分区：
文献类型：
--
作者：
Alavi, Mehran;Hamidi, Mehrdad
在过去的几十年里，注射给药系统在癌症治疗中的应用取得了长足的发展。这些改进包括脂质体、脂质纳米颗粒（LNPs）和其他具有或不具有大分子偶联物的纳米颗粒。例如，由聚乙二醇修饰的多柔比星脂质体是美国食品和药物管理局批准的第一个具有抗癌作用的脂质体，而Abraxane（由紫杉醇负载的修饰白蛋白纳米颗粒）最近被证实用于治疗乳腺癌。最近，LNPs给药系统是一种新兴的技术，与传统的脂质体和使用免费药物治疗癌症的化疗相比，具有许多优点。具有生物相容性、抗肿瘤药物控释和缓释、毒性低等特点。对这些药物输送系统进行的有价值的实验为治疗耐多药癌症和降低心脏毒性提供了更好的方法。LNPs在乳腺癌和前列腺癌的化疗靶向治疗中具有很高的功能。这种目标行为的基础已被证明是被动和主动的目标。本综述的主要目的是综述目前基于脂质体的药物传递系统在靶向抗癌化疗中的地位。
Considerable development in the application of injectable drug delivery systems for cancer therapy has occurred in the last few decades. These improvements include liposomes, lipid nanoparticles (LNPs), and other nanoparticles with or without macromolecular conjugates. For example, liposomal doxorubicin modified by poly(ethylene glycol) (Doxil) was the first liposome with anti-cancer effects which was approved by the US Food and Drug Administration, whereas Abraxane (modified albumin nanoparticles loaded by paclitaxel) was recently confirmed for the treatment of breast cancer. Recently, drug delivery systems by LNPs are an emerging technology with numerous advantages over conventional liposomes and chemotherapy using free drug treatment of cancer. These properties are biocompatibility, controlled and sustained release of anti-tumor drugs, and lower toxicity. Valuable experiments on these drug delivery systems offer better treatment of multidrug-resistant cancers and lower cardiotoxicity. LNPs have been presented with high functionality in chemotherapeutic targeting of breast and prostate cancer. The basis for this targeting behavior has been shown to be both passive and active targeting. The main objective of this review was an overview of the current position of the liposome-based drug delivery systems in targeted anticancer chemotherapy.